BUENA, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2017.

Third Quarter 2017 Highlights

  • Total revenues of $13.7 million in the third quarter of 2017, a decrease of 15% over the same quarter in 2016.

  • Total net revenues generated from the sale of our generic topical and injectable pharmaceutical products for the third quarters of 2017 and 2016 of $11.8 million and $13.9 million, respectively, a decrease of 15% over the same quarter last year.

  • Total net revenues generated from contract manufacturing services and other income for the third quarters of 2017 and 2016 of $1.9 million and $2.3 million, respectively.

  • Total net international revenues for the third quarters of 2017 and 2016 of $3.6 million and $2.7 million, respectively.

  • Gross margin for the third quarter of 2017 equaled 24% as compared to 50% in the third quarter of 2016.

  • Operating loss was $5.4 million in the third quarter of 2017, compared to operating income of $0.3 million in the same quarter in 2016. Operating loss was $4.2 million for the nine months ended September 30, 2017, compared to operating income of $2.2 million in 2016.

  • Our operating results in the third quarter of 2017 include $4.6 million in research and development costs, compared to $4.0 million in the same quarter in 2016.

  • As a result of the fluctuation in foreign exchange rates during the third quarter of 2017, we recorded a non-cash gain in the amount of $1.7 million related to the foreign currency translation of our intercompany loans to three of our wholly-owned subsidiaries; and other balances held in currencies other than local currency, compared to a non-cash gain in the amount of $0.4 million in the same quarter in 2016.

  • The Company received approval for four ANDAs during the three months ended September 30, 2017 for the following products: Desonide Lotion, 0.05%, Erythromycin Topical Gel USP, 2%, Clobetasol Propionate Cream USP, 0.05% Emollient and, Triamcinolone Acetonide Cream USP, 0.1%.  All of these products have been launched except Desonide Lotion, 0.05%, which is expected to be launched in the fourth quarter of 2017.  Desonide Lotion, 0.05% was submitted under a partnered development agreement by Teligent, Inc. with Impax Laboratories, Inc.  

Revised Full Year 2017 Financial Guidance

  • The Company now expects total revenue between $65 million and $67 million for the year ending December 31, 2017.

  • As a result of revised total revenue, the Company now anticipates gross margin of 38% to 40% for the year ending December 31, 2017.

“This third quarter has been challenging for Teligent. These results and our revised outlook for the remainder of the year, are a result of the knock-on effect of ANDA approval delays and increased competition in one of our largest products,” said Jason Grenfell-Gardner, President and Chief Executive Officer.

Mr. Grenfell-Gardner continued, “Despite the challenging environment, we have made significant progress on the expansion of our manufacturing facility in New Jersey to support our long-term commitment to executing our TICO strategy by expanding our specialty generic pharmaceutical product portfolio in the topical, injectable, complex, and ophthalmic markets.  We now market twenty-one products in the US generic topical market, another four products in the US hospital injectable market, and have thirty approved generic products in the Canadian market.”

“We received approval of four ANDAs in the third quarter, we now have 32 ANDAs on file with the US FDA and based on QuintilesIMS Health data as of September 2017, the current total addressable market of these pipeline ANDAs is estimated at approximately $2.0 billion. Significantly, 90% of this total addressable market is for products filed in Generic Drug User Fee Amendments (GDUFA) Year 3 or later,” Mr. Grenfell-Gardner concluded.

The Company will hold a conference call at 4:30 pm ET today, Monday, November 6, 2017 to discuss the third quarter 2017 results.

The Company invites you to listen to the call by dialing 1-866-393-8366. International participants should call 1-409-350-3154. Participants should ask to be joined into the Teligent, Inc. call.

This call is being webcast and can be accessed in the Investor Relations Section of Teligent Inc.'s website at www.teligent.com.

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as “plan,” “believe,” “continue,” “should” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in Teligent, Inc.’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

Non-GAAP Financial Measures

In addition to reporting financial information required in accordance with U.S. generally accepted accounting principles (GAAP), Teligent is also presenting EBITDA and Adjusted EBITDA which are non-GAAP financial measures. Since EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs are non-GAAP financial measures, they should not be used in isolation or as a substitute for consolidated statements of operations and cash flow data prepared in accordance with GAAP. In addition, Teligent's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies.

Adjusted EBITDA, as defined by the Company, is calculated as follows:

Net income (loss), plus:

Depreciation expense

Amortization of intangibles

Loss on impairment

Interest expense, net

Non-cash interest expense

Provision for income taxes

Inventory step up and acquisition costs related to acquisitions

Foreign currency exchange gain/loss

Non-cash expenses, such as share-based compensation expense

The Company believes that Adjusted EBITDA is a meaningful indicator, to both Company management and investors, of the past and expected ongoing operating performance of the Company. EBITDA is a commonly used and widely accepted measure of financial performance. Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add back of non-cash and non-recurring operating expenses which have little to no bearing on cash flows and may be subject to uncontrollable factors not reflective of the Company's true operational performance.

While the Company uses EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs in managing and analyzing its business and financial condition and believes these non-GAAP financial measures to be useful to investors in evaluating the Company's performance, it is open to certain shortcomings. EBITDA and Adjusted EBITDA do not take into account the impact of capital expenditures on either the liquidity or the financial performance of the Company and likewise omit share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense.  Due to the inherent limitations of EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs, the Company's management utilizes comparable GAAP financial measures to evaluate the business in conjunction with EBITDA and Adjusted EBITDA and encourages investors to do likewise.

The Company also presents a non-GAAP financial measure of adjusted net income (loss) and adjusted net income (loss) per diluted share, to the show the adjusted net income when EBITDA adjustments are added back or subtracted out of the traditional GAAP reported net income (loss).  Adjusted diluted earnings per share, as defined by the Company, is equal to adjusted net income divided by the actual or anticipated diluted share count for the applicable period.

(in thousands, except shares and per share information)
 Three months ended September 30, Nine months ended September 30,
 2017 2016 2017 2016
Product sales, net$13,634  $15,709  $51,782  $48,156 
Research and development services and other income21  442  172  790 
Total revenues13,655  16,151  51,954  48,946 
Costs and Expenses:       
Cost of revenues10,313  8,137  29,641  23,421 
Selling, general and administrative expenses4,121  3,694  13,126  10,813 
Product development and research expenses4,606  4,017  13,387  12,496 
Total costs and expenses19,040  15,848  56,154  46,730 
Operating (loss) income(5,385) 303  (4,200) 2,216 
Other Income (Expense):       
Foreign currency exchange gain1,744  364  6,645  1,295 
Interest and other expense, net(2,663) (3,347) (8,731) (9,997)
Loss before income tax expense(6,304) (2,680) (6,286) (6,486)
Income tax expense24  23  130  68 
Net loss$(6,328) $(2,703) $(6,416) $(6,554)
Basic and diluted loss per share$(0.12) $(0.05) $(0.12) $(0.12)
Weighted average shares of common stock outstanding:       
Basic and diluted shares53,391,948  53,093,368  53,297,889  53,061,630 

(in thousands, except shares and per share information)
 September 30, December 31,
 2017 2016*
Current assets:   
Cash and cash equivalents$38,231  $66,006 
Accounts receivable, net27,568  21,735 
Inventories14,199  12,708 
Prepaid expenses and other receivables2,390  2,847 
Total current assets82,388  103,296 
Property, plant and equipment, net57,248  26,215 
Intangible assets, net56,112  52,465 
Goodwill476  446 
Other784  804 
Total assets$197,008  $183,226 
Current liabilities:   
Accounts payable$8,865  $4,614 
Accrued expenses16,260  10,349 
Total current liabilities25,125  14,963 
Convertible 3.75% senior notes, net of debt discount and debt issuance costs (face of $143,750)118,463  111,391 
Deferred tax liability239  205 
Total liabilities143,827  126,559 
Stockholders’ equity:   
Common stock, $0.01 par value, 100,000,000 shares authorized;   
53,391,948 and 53,148,441 shares issued and outstanding   
as of September 30, 2017 and December 31, 2016, respectively554  551 
Additional paid-in capital105,418  102,624 
Accumulated deficit(51,319) (44,903)
Accumulated other comprehensive loss, net of taxes(1,472) (1,605)
Total stockholders’ equity53,181  56,667 
Total liabilities and stockholders' equity$197,008  $183,226 

* Derived from the audited December 31, 2016 financial statements

For the nine months ended September 30, 2017 and 2016
(in thousands)
 September 30, 2017 September 30, 2016
Cash flows from operating activities:   
Net loss$(6,416) $(6,554)
Non-cash expenses7,862  11,018 
Changes in operating assets and liabilities(4,106) (1,644)
Net cash (used in) provided by operating activities(2,660) 2,820 
Net cash used in investing activities(26,002) (15,378)
Net cash provided by (used in) financing activities269  (71)
Effect of exchange rate on cash and cash equivalents618  70 
Net decrease in cash and cash equivalents(28,393) (12,629)
Cash and cash equivalents at beginning of period66,006  87,191 
Cash and cash equivalents at end of period$38,231  $74,632 

(in thousands)
 Three months ended September 30, Nine months ended September 30,
 2017 2016 2017 2016
Gross product sales$53,460  $64,943  $174,504  $136,329 
Reduction to gross product sales:       
Chargebacks and billbacks30,150  43,161  104,255  82,564 
Sales discounts and other allowances11,559  7,881  26,174  19,580 
Total reduction to gross product sales41,709  51,042  130,429  102,144 
Product sales, net11,751  13,901  44,075  34,185 
Contract manufacturing product sales1,883  1,808  7,707  13,971 
Total product sales, net$13,634  $15,709  $51,782  $48,156 

(in thousands)
  Three months ended September 30, Nine months ended September 30,
  2017 2016 2017 2016
Net loss $(6,328) $(2,703) $(6,416) $(6,554)
Depreciation 442  283  1,264  679 
Amortization of intangibles 747  709  2,143  2,146 
Loss on impairment 113    113   
Interest expense, net 231  1,209  1,660  3,780 
Non-cash interest expense 2,432  2,139  7,071  6,217 
Provision for income taxes 24  23  130  68 
EBITDA (2,339) 1,660  5,965  6,336 
Inventory step-up, related to acquisition       530 
Foreign currency exchange gain (1,744) (364) (6,645) (1,295)
Non-cash stock-based compensation expense 688  746  2,427  2,255 
Adjusted EBITDA (3,395) 2,042  1,747  7,826 
Product development and research expenses 4,606  4,017  13,387  12,496 
Adjusted EBITDA, before Product development and research expenses $1,211  $6,059  $15,134  $20,322 

(in thousands, except share and per share information)
 Three months ended September 30, Nine months ended September 30,
 2017 2016 2017 2016
Net loss$(6,328) $(2,703) $(6,416) $(6,554)
Non-cash interest expense2,432  2,139  7,071  6,217 
Provision for income taxes24  23  130  68 
Amortization of intangibles747  709  2,143  2,146 
Loss on impairment113    113   
Inventory step-up, related to acquisition      530 
Foreign currency exchange gain(1,744) (364) (6,645) (1,295)
Non-cash stock-based compensation expense688  746  2,427  2,255 
Adjusted net (loss) income$(4,068) $550  $(1,177) $3,367 
Non-GAAP adjusted net (loss) income per diluted share$(0.08) $0.01  $(0.02) $0.05 


Jenniffer Collins
Teligent, Inc.
(856) 697-4379